Virbac SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Virbac SA Comment On FY 2013 Guidance
Virbac SA announced that it expects to report 5% to 7% organic growth and a further 0.5 point improvement of operating profitability in fiscal year 2013. The Company also expects to report a double digit growth of its revenues and operating profit in full year 2013.
Latest Key Developments in Pharmaceuticals
- Ariad Pharmaceuticals's AP26113 receives FDA breakthrough therapy designation
- HISAMITSU PHARMACEUTICAL CO INC revises consolidated mid-year outlook for FY 2015
- Amgen Inc publishes two phase 3 studies showing cholesterol-lowering medication evolocumab significantly reduced LDL cholesterol
- Sagent Pharmaceuticals announces acquisition of Omega Laboratories
- Share this
- Digg this